• Record SOZO Core Business TCV of $6.3 million
• Additional major commercial payor providing coverage from July 1, 2025
• Qualified for $US5.0 million Tranche 2 funds under existing growth capital facility

ImpediMed Limited (ASX:IPD) has announced its Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ending 30 June 2025 (Q4 FY25). The company recorded record SOZO Core Business Total Contract Value (TCV) of $6.3 million, a direct result of strengthening the sales team and processes. This represents a significant increase from $4.9 million in Q3 FY25. The company saw a 100% increase in US SOZO sales, with 44 units sold, including a 9-unit contract with Legacy Health, a major health system in the Pacific Northwest. While no units were sold in the rest of the world compared to 14 in Q3 FY25, this was due to the timing of distributor inventory restocking. The company's Australian distributor placed an 18-unit order in July. Annual Recurring Revenue (ARR) for the Core Business increased to $14.0 million, up from $13.7 million in Q3 FY25. The company also received an additional major commercial payor coverage from July 1, 2025, significantly increasing the depth of coverage across multiple states. Financially, the company had net cash outflows from operating activities of $3.5 million, in line with Q3 FY25. The cash balance at the end of the quarter was $22.2 million, excluding the $US5.0 million Tranche 2 funds from the company's growth capital facility, which was drawn down in July 2025.

With lead flow continuing to strengthen, higher reimbursement and opportunities to expand within the existing customer base, the company is well positioned to maintain this momentum and deliver further sales growth in FY26.